$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

$tnfa Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041328 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.930M	$1.907M
YoY Change		1.22%	16.22%
% of Gross Profit
Research & Development		$1.912M	$1.803M
YoY Change		6.05%	-34.85%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$1.912M	$1.803M
YoY Change		6.05%	-59.09%
Operating Profit		-$3.843M	-$3.710M
YoY Change		3.58%	-15.84%
Interest Expense		$2.710M	$16.15K
YoY Change		16680.19%	-1731.31%
% of Operating Profit
Other Income/Expense, Net		$7.886M	$16.15K
YoY Change		48721.09%	-101.53%
Pretax Income		$4.043M	-$3.694M
YoY Change		-209.46%	-32.44%
Income Tax
% Of Pretax Income
Net Earnings		$4.043M	-$3.694M
YoY Change		-209.46%	-32.44%
Net Earnings / Revenue
Basic Earnings Per Share		$0.06	-$0.09
Diluted Earnings Per Share		$0.06	-$94.60K
COMMON SHARES
Basic Shares Outstanding	50.90M shares	44.93M shares	38.06M shares
Diluted Shares Outstanding		44.95M shares	39.05M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$8.470M	$7.084M
YoY Change		19.56%	-53.93%
Cash & Equivalents	$2.681M	$298.3K	$309.9K
Short-Term Investments		$8.170M	$6.774M
Other Short-Term Assets		$1.260M	$993.1K
YoY Change		26.87%	74.29%
Inventory
Prepaid Expenses	$893.2K	$1.263M	$993.1K
Receivables
Other Receivables
Total Short-Term Assets	$5.816M	$9.736M	$8.077M
YoY Change	7.67%	20.53%	-49.35%
LONG-TERM ASSETS
Property, Plant & Equipment		$90.00K	$155.1K
YoY Change		-41.98%	141.52%
Goodwill	$10.50M	$10.50M	$10.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments		$1.500M	$1.500M
YoY Change		0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$12.05M	$12.09M	$12.15M
YoY Change	-0.76%	-0.53%	0.75%
TOTAL ASSETS
Total Short-Term Assets	$5.816M	$9.736M	$8.077M
Total Long-Term Assets	$12.05M	$12.09M	$12.15M
Total Assets	$17.86M	$21.83M	$20.23M
YoY Change	1.84%	7.88%	-27.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.716M	$2.034M	$1.717M
YoY Change	39.02%	18.43%	-16.37%
Accrued Expenses	$637.1K	$685.9K	$324.6K
YoY Change	101.2%	111.3%	733.89%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.988M	$5.696M	$1.781M
YoY Change	80.14%	219.82%	-14.89%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$20.00K	$123.1K
YoY Change		-83.76%	373.94%
Total Long-Term Liabilities	$100.5K	$20.52K	$123.1K
YoY Change	32.39%	-83.33%	373.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.988M	$5.696M	$1.781M
Total Long-Term Liabilities	$100.5K	$20.52K	$123.1K
Total Liabilities	$5.089M	$5.716M	$1.904M
YoY Change	78.87%	200.21%	-10.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$102.0M	-$97.09M	-$90.01M
YoY Change	8.77%	7.86%
Common Stock	$2.019K	$112.4M	$108.2M
YoY Change	-100.0%	3.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.37M	$15.50M	$18.33M
YoY Change
Total Liabilities & Shareholders Equity	$17.86M	$21.83M	$20.23M
YoY Change	1.84%	7.88%	-27.77%

Cashflow Statement

Concept	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	$4.043M	-$3.694M
YoY Change	-209.46%	-32.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.160M	-$4.087M
YoY Change	-22.69%	-36.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$3.360M	-$2.268M
YoY Change	-248.16%	-141.25%
Cash From Investing Activities	$3.360M	-$2.268M
YoY Change	-248.16%	-141.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	5.550M
YoY Change	-100.0%	2748.07%
NET CHANGE
Cash From Operating Activities	-3.160M	-4.087M
Cash From Investing Activities	3.360M	-2.268M
Cash From Financing Activities	0.000	5.550M
Net Change In Cash	200.0K	-805.2K
YoY Change	-124.84%	7.03%
FREE CASH FLOW
Cash From Operating Activities	-$3.160M	-$4.087M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	MYMD	Warrant Issuance Expenses WarrantIssuanceExpenses		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001321834
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	MYMD	Warrant Liabilities WarrantLiabilities		usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent		usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
CY2022Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2022Q3	MYMD	Warrant Issuance Expenses WarrantIssuanceExpenses		usd
	MYMD	Warrant Issuance Expenses WarrantIssuanceExpenses		usd
CY2022Q3	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q3	MYMD	Casualty Gain Loss CasualtyGainLoss		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023Q2	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
CY2023Q3	MYMD	Deemed Dividend Preferred Stock DeemedDividendPreferredStock		usd
CY2022Q1	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Officers Compensation OfficersCompensation		usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MYMD	Accrual Of Series F Convertible Preferred Stock Dividend AccrualOfSeriesFConvertiblePreferredStockDividend		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants		usd
	MYMD	Initial Fair Value Of Derivative Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfDerivativeLiabilitiesPursuantToIssuanceOfWarrants		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36268
	dei	Entity Registrant Name EntityRegistrantName	MyMD Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NJ
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2983783
	dei	Entity Address Address Line1 EntityAddressAddressLine1	855 N. Wolfe Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 601
	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21205
	dei	City Area Code CityAreaCode	(856)
	dei	Local Phone Number LocalPhoneNumber	848-8698
	dei	Security12b Title Security12bTitle	Shares of Common Stock, no par value
	dei	Trading Symbol TradingSymbol	MYMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50900715	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298318	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	749090	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8174283	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4086902	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1263478	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	565787	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	9736079	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5401779	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90918	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2023Q3	us-gaap	Goodwill Goodwill	10498539	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10498539	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	12089457	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12138201	usd
CY2023Q3	us-gaap	Assets Assets	21825536	usd
CY2022Q4	us-gaap	Assets Assets	17539980	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2033840	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2673221	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72626	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	898100	usd
CY2023Q3	MYMD	Warrant Liabilities WarrantLiabilities	2457000	usd
CY2023Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	204194	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5695742	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2768983	usd
CY2023Q3	MYMD	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	20519	usd
CY2022Q4	MYMD	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	75941	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	20519	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	75941	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5716261	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2844924	usd
CY2023Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47000365	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47000365	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	112441633	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	108309436	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97085475	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93758904	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15500682	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21825536	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17539980	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1334690	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1554244	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4202594	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4296119	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1912322	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1803232	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4907196	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6596942	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	595576	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	352417	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2341915	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	581663	usd
	MYMD	Warrant Issuance Expenses WarrantIssuanceExpenses	762834	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3842588	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3709893	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12214539	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11474724	usd
CY2023Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	139056	usd
CY2022Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	15453	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	339731	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	21559	usd
CY2023Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-500	usd
CY2022Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1200	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-714	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-4849	usd
CY2023Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2324	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1899	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-371	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1754	usd
CY2023Q3	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2566900	usd
	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2251700	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5356000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8166000	usd
CY2023Q3	MYMD	Casualty Gain Loss CasualtyGainLoss	-178198	usd
	MYMD	Casualty Gain Loss CasualtyGainLoss	-178198	usd
	MYMD	Casualty Gain Loss CasualtyGainLoss	4442	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7885582	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16152	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10578148	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22906	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4042994	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3693741	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1636391	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11451818	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4042994	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3693741	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1636391	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11451818	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1158051	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1690180	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2884943	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3693741	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3326571	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11451818	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44949097	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39046852	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41710705	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38502163	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44949097	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39046852	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41710705	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38502163	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1511732	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	158333	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	69068	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13094059	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4167653	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	255945	usd
CY2023Q2	MYMD	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	255944	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	373796	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1677271	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10741770	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4042994	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	255945	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	255945	usd
CY2023Q3	MYMD	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	214175	usd
CY2023Q3	MYMD	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	214175	usd
CY2023Q3	MYMD	Stock Issued During Period Value Accelerated Conversion Of Convertible Securities StockIssuedDuringPeriodValueAcceleratedConversionOfConvertibleSecurities	41770	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	391548	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	595576	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15500682	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4122034	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	81002	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	15998	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19622140	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3636043	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	132246	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16118343	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16118343	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3693741	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3693741	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5550028	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5550028	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	138587	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	135620	usd
CY2022Q3	MYMD	Stock Issued During Period Value Compensation Of Warrants StockIssuedDuringPeriodValueCompensationOfWarrants	78210	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	18327047	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	18327047	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1636391	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11451818	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-714	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-4849	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-371	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1754	usd
	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2251700	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8166000	usd
	us-gaap	Officers Compensation OfficersCompensation	769657	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1429693	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	293700	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	142565	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	55168	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	78210	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	154585	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	697691	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-113217	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-639381	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	730683	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	168	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1496	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11047995	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10021664	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13338466	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	4774405	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9250000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4088466	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4225595	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	14685689	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5550028	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14685689	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5550028	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-450772	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-246041	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	749090	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	555967	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	298318	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309926	usd
	MYMD	Accrual Of Series F Convertible Preferred Stock Dividend AccrualOfSeriesFConvertiblePreferredStockDividend	204194	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	53196	usd
	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants	10623000	usd
	MYMD	Initial Fair Value Of Derivative Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfDerivativeLiabilitiesPursuantToIssuanceOfWarrants	3149800	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zIvFMB0ikyX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b) <span id="xdx_869_zKx6bCmj93cc">Use of Estimates and Judgments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for recording research and development expenses, impairment of intangible assets and the valuation of share-based payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	MYMD	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	2324	usd
CY2022Q3	MYMD	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	1899	usd
	MYMD	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	371	usd
	MYMD	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	1754	usd
CY2023Q3	MYMD	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	500	usd
CY2022Q3	MYMD	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	1200	usd
	MYMD	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	714	usd
	MYMD	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	4849	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9250000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9000000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_za1JuYSubtU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i) <span id="xdx_862_zbP6tK7jp1Bb">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90918	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72626	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20519	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75941	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	19255	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	19260	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	57614	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	58372	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	54012	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	19391	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	74451	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5814	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	99656	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6511	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	93145	usd
CY2023Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24542327	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13893329	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24542327	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13893329	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The Series F Preferred Stock cannot be converted to Common Stock if the holder and its affiliates would beneficially own more than 4.99% or 9.99% at the election of the holder of the outstanding Common Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder to us and such increase or decrease will apply only to the holder providing such notice
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47000365	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company Common Stock
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1158051	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1690180	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	3149800	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	314311	usd
	MYMD	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	10623000	usd
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	898100	usd
CY2023Q3	MYMD	Probability Of Default ProbabilityOfDefault	8.2	pure
CY2023Q3	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	871323	shares
CY2023Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	766503	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2347852	usd
	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	871323	shares
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	766503	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	4695704	usd
	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants	10623000	usd
	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	762834	usd
CY2023Q3	MYMD	Warrant Liabilities WarrantLiabilities	2457000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298318	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8174283	usd
	MYMD	Loss From Operations LossFromOperations	-1636391	usd
CY2023Q3	MYMD	Working Capital WorkingCapital	4040337	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15500682	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97085475	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11047995	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1636391	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	697691	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-639381	usd
	MYMD	Change In Fair Value Of Warrant And Derivative Liabilities ChangeInFairValueOfWarrantAndDerivativeLiabilities	-10417700	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2341915	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7321445	shares
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1347904	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2356555	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	685936	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	316666	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2033840	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2673221	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476737	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y7M20D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3845000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.29
	MYMD	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P8Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4176737	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.59
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue	2.59
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4145000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.54
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.42
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding	P8Y5M19D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1214999	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.38
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	1.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M25D
CY2023Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	550000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	11435	usd
CY2022Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	6498	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	36113	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	30517	usd

Files In Submission

Name	View Source	Status
mymd-20230930_def.xml	Edgar Link	unprocessable
mymd-20230930_pre.xml	Edgar Link	unprocessable
0001493152-23-041328-index-headers.html	Edgar Link	pending
0001493152-23-041328-index.html	Edgar Link	pending
0001493152-23-041328.txt	Edgar Link	pending
0001493152-23-041328-xbrl.zip	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mymd-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mymd-20230930_cal.xml	Edgar Link	unprocessable
mymd-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q4 Form 10-Q Financial Statement

#000149315223041328 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q4 Form 10-Q Financial Statement

#000149315223041328 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa